Stifel Financial’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
Other funds holding ELVN
Stifel Financial's ELVN Position: Q3 2026 in Review
Stifel Financial increased its Enliven Therapeutics (ELVN) stake by 2.1% in Q3 2026, buying an estimated $6.05K and bringing the position to 5,294 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #3423.
Stifel Financial first reported a position in ELVN in Q1 2026 and has held it in 3 quarters since. The position peaked at $311K in Q1 2026. 216 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.
- Stifel Financial held 5,294 shares of Enliven Therapeutics worth $243K as of Q3 2026.
- Stifel Financial bought 111 Enliven Therapeutics shares in Q3 2026, an estimated $6.05K.
- Enliven Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q3 2026, its #3423 holding.
- Stifel Financial first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Stifel Financial's Enliven Therapeutics position peaked at $311K in Q1 2026.
- 216 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.
Based on Stifel Financial's 13F filing for Q3 2026, filed 12 Nov 2026.